4Liu QW, Fu JH, Luo KJ, et al. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma[J]. Dis Esophgus, 2011, 24(5): 374-380.
5Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity[J]. Int J Radiat Oncol Biol Phys, 2008, 70(2): 391-395.
6Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Intemistische Onkologie[J]. Ann Oncol, 2009, 20(10): 1667-1673.
7Ruhstaller T, Pless M, Dietrich D, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase I B/ II Trial (SAKK 75/06) [J]. J Clin Oncol, 2011, 29(6): 626-631.
8Gold P J, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)[J]. J Thorac Oncol, 2010, 5(9): 1472-1476.
9Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase II trial of single agent eetuximab in advanced esophageal and gastric adenocarcinoma[J]. Ann Oncol, 2011, 22(6): 1367-1373.
10Rodriguez CP, Adelstein D J, Rice TW, et al. A phase II study of perioperative concurrent chemoradiotherapy, gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer[J]. J Thorac Oncol, 2010, 5(2): 229-235.
